

Pharmaceutical innovation and access to medicines

Fourth European Healthcare Policy Deciders Forum

LSE, 17 February 2011

Christophe Roeland


DG Enterprise & industry

Unit F/5 - Food & Healthcare Industries, Biotechnology



European Commission
Enterprise and Industry

Promoting innovation: a holistic approach



European Commission initiatives

- **Pharmaceutical Forum 2005-2008:** recommendations to ensure adequate balance between access to medicines, control of pharmaceutical expenditure and reward for innovation
- Process created **momentum for collaborative initiatives** between stakeholders
- Sept. 2010: V.P. Tajani launched stakeholder **Process on Corporate Responsibility in the field of Pharmaceuticals**
 - Transparency and deontology
 - Access to medicines in third countries (focus on Africa)
 - Access to medicines in Europe

Access to medicines in Europe

- Objective: find **common, non-regulatory approaches** to ensure timely and equitable access to medicines after their marketing authorisation.
- Voluntary participation: Member States and representative organisations will volunteer experts for the projects
- Concrete projects to explore non regulatory conditions for better access to medicines after their marketing authorisation.
- Steering group to generate **momentum** for effective development of projects and put **forward experienced-based recommendations**.

Five projects...

- **... to encourage access to innovative treatments**
 1. Mechanism of coordinated access to **orphan medicinal products**
 2. Capacity building on **contractual agreements** for innovative medicines
- **... to promote a responsible environment for access**
 3. Market access for **biosimilars**
 4. Facilitating supply in **small markets**
 5. Promoting a good governance for **non-prescription medicines**

Vision 2020



**Effective cooperation between stakeholders
to improve access to medicines**